Enrollment Status: Closed
HVTN 136/HPTN 092 is a phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or subcutaneous infusions in healthy adults who do not have HIV.
Are you interested in advancing the science of HIV Prevention, or have your loved ones been impacted by HIV?
We have an exciting opportunity for YOU to help move research forward for HIV PREVENTION.
Antibodies are proteins the body makes to help fight disease in response to exposure to avirus. The body is constantly creating antibodies to help prevent illnesses. In this study, participants will receive investigational antibodies to see if this could be a new PrEP or HIV prevention treatment in the future.
We need volunteers who are: